Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia - PubMed (original) (raw)
Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia
R H Mak. J Pediatr. 1996 Jul.
Free article
Abstract
Objective: To determine whether anemia is important in the pathogenesis of metabolic abnormalities in insulin, amino acid, and lipid metabolism in uremia.
Methods: Twelve adolescents (15 +/- 1 years of age) undergoing long-term dialysis were studied before and after correction of their anemia by human recombinant erythropoietin at a mean interval of 6 months. Six patients received hemodialysis, and six received continuous-cycling peritoneal dialysis. Insulin sensitivity was measured by the euglycemic clamp technique and insulin secretion by the hyperglycemic clamp technique in these patients.
Results: Hematocrit increased from 0.219 +/- 0.006 to 0.344 +/- 0.007 (p <0.01). Ferritin concentration did not change significantly (11,252 +/- 356 mg/dl to 785 +/- 226 mg/dl). Serum iron concentration decreased from 134 +/- 13 mg/dl to 83 +/- 11 mg/dl, and percentage saturation decreased from 56 +/- 4 to 41 +/- 5 (p <0.05 in both cases). There were no significant changes in weight, height, blood pressure, caloric intake, triceps skinfold thickness, or arm muscular area. There were also no significant changes in serum calcium, phosphate, bicarbonate, albumin, creatinine, or blood urea nitrogen concentration. Insulin sensitivity increased by 33% (p <0.01), but insulin secretion did not change significantly. Insulin sensitivity during the euglycemic clamp studies in patients before erythropoietin therapy was lower (145 +/- 10 mg/m2 per minute; p <0.01) than published normal values (201 +/- 12 mg/m2 per minute) and was normal after erythropoietin therapy (193 +/- 11 mg/m2 per minute). Insulin secretion was low in patients before erythropoietin therapy (44 +/- 8 microU/ml) compared with published normal values (68 +/- 6 microU/ml) and did not change after erythropoietin therapy (46 +/- 4 microU/ml). Plasma concentrations of branched-chain amino acids and lipids in the patients were compared with values from eight healthy adolescents. Plasma concentrations of valine, leucine, and isoleucine were low before treatment and were normal after 6 months of erythropoietin therapy. Plasma concentrations of triglycerides, total cholesterol, and low-density lipoprotein cholesterol were all high before treatment and were normal after treatment of anemia.
Conclusions: Treatment of anemia by erythropoietin reversed insulin resistance as well as amino acid and lipid abnormalities in adolescents undergoing dialysis.
Similar articles
- Metabolic effects of erythropoietin in patients on peritoneal dialysis.
Mak RH. Mak RH. Pediatr Nephrol. 1998 Oct;12(8):660-5. doi: 10.1007/s004670050524. Pediatr Nephrol. 1998. PMID: 9811391 Clinical Trial. - Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia.
Mak RH. Mak RH. Am J Physiol. 1996 May;270(5 Pt 2):F839-44. doi: 10.1152/ajprenal.1996.270.5.F839. Am J Physiol. 1996. PMID: 8928846 - Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V, Martimbianco L, Vasile A. Allegra V, et al. Nephrol Dial Transplant. 1997 May;12(5):924-32. doi: 10.1093/ndt/12.5.924. Nephrol Dial Transplant. 1997. PMID: 9175044 Clinical Trial. - [Recombinant human erythropoietin in the therapy of anemia in hemodialyzed patients].
Kakuk G, Kárpáti I, Mátyus J. Kakuk G, et al. Orv Hetil. 1990 Oct 28;131(43):2365-6, 2369-71. Orv Hetil. 1990. PMID: 2234936 Review. Hungarian. - Impact of erythropoietin on the dialysis prescription.
Van Wyck DB. Van Wyck DB. Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):71-5. Am J Kidney Dis. 1991. PMID: 1928083 Review.
Cited by
- Insulin resistance in patients with chronic kidney disease.
Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Liao MT, et al. J Biomed Biotechnol. 2012;2012:691369. doi: 10.1155/2012/691369. Epub 2012 Aug 7. J Biomed Biotechnol. 2012. PMID: 22919275 Free PMC article. Review. - Insulin and its role in chronic kidney disease.
Mak RH. Mak RH. Pediatr Nephrol. 2008 Mar;23(3):355-62. doi: 10.1007/s00467-007-0611-2. Epub 2007 Oct 11. Pediatr Nephrol. 2008. PMID: 17929061 Review. - Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure.
Sampanis Ch. Sampanis Ch. Hippokratia. 2008 Jan;12(1):22-7. Hippokratia. 2008. PMID: 18923754 Free PMC article. - Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system.
Wang L, Di L, Noguchi CT. Wang L, et al. Int J Biol Sci. 2014 Aug 23;10(8):921-39. doi: 10.7150/ijbs.9518. eCollection 2014. Int J Biol Sci. 2014. PMID: 25170305 Free PMC article. Review. - Erythropoietin action in stress response, tissue maintenance and metabolism.
Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Zhang Y, et al. Int J Mol Sci. 2014 Jun 10;15(6):10296-333. doi: 10.3390/ijms150610296. Int J Mol Sci. 2014. PMID: 24918289 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical